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Macroscale delivery systems that can be locally implanted on the tumor tissue as well 
as avoid all the complications associated to the systemic delivery of therapeutics have 
captured researchers’ attention, in recent years. Particularly, the microneedle-based 
devices can be used to efficiently deliver both small and macro-molecules, like 











anticancer therapies. Such capacity prompted the application of microneedle devices 
for the development of new anticancer vaccines that can permeate the tumor tissue 
and simultaneously improve the effectiveness of therapeutic agents. 
Based on the promising results demonstrated by the microneedle systems in the local 
administration of anticancer therapeutics, this review summarizes the different 
microneedle formulations developed up to now aimed for application on cancer therapy 
(mphasizing those produced with polymers). Additionally, the microneedles’ general 
properties, type of therapeutic approach and its main advantages are also highlighted. 
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1. Introduction 
Despite all the efforts, cancer remains as one of the leading health problems affecting 
the world population. In fact, recent data clearly show that the cancer incidence has 
been increasing in the last decades [1, 2]. On the other hand, both the conventional 
(e.g. chemotherapy and radiotherapy) and novel (e.g. nanomedicines) anticancer 
therapeutics present sub-optimal efficacies [3-5]. Further, the clinical translation of 
highly promising nanoparticle-based anticancer therapies has been severely hindered 
by their low capacity to accumulate within the tumor tissue (i.e. less than 0.7% of the 
administered dose reach the tumor site) [6, 7]. Moreover, the nanomedicines’ high 
complexity also difficult the synthesis procedures scale-up and the reproducibility of the 
therapeutics outcome [5]. Therefore, in the recent years, researchers started to re-
explore macroscale delivery devices (e.g. microneedle systems and hydrogels) that 












Particularly, microneedle devices have been showing promising results that support its 
application as anti-tumoral therapies. The concept of microneedle-based drug delivery 
systems was firstly described at more than three decades ago and their practical 
clinical application started to be highly pursued within the past 15 years [11]. Since 
then, microneedles have been fabricated using a myriad of materials including metals, 
polymers, glass, and ceramics as well as in a wide variety of shapes and 
arrangements, in order to meet the desired clinical requirements [12-14]. Further, 
during the last decade, extensive preclinical evaluation studies have been performed 
by the scientific community for validating the microneedles’ application as drug delivery 
systems in the biomedical field. To date, microneedles have been used in the pre-
clinical and clinical investigation to i) enhance the passive transdermal delivery, ii) 
evaluate the vaccines’ antigenicity, iii) evaluate altered protein pharmacokinetics and 
pharmacodynamics, iv) determine pain and other perceptions associated with 
microneedle delivery and lately v) transport anticancer therapeutics [15-20]. 
In cancer therapy, the application of microneedle devices has been explored to trigger 
anticancer immunologic responses (e.g. antigens, immune adjuvants, genetic material) 
or to deliver anticancer compounds (e.g. drugs and nanoparticles) [21-25]. In that way, 
the local application of microneedle-based systems can increase the distribution and 
the amount of drug that reaches the deeper regions of the tumors, while minimizes the 
therapeutics leakage to adjacent tissues and the side effects [18, 26, 27]. Further, the 
microneedles also facilitate the combination of different drugs in one single therapy as 
well as allows their temporally controlled release, which can be used in the drug 
development phase for screening the best therapeutic combinations and in the clinic to 
enhance the anti-tumoral effect [28-30]. Therefore, this review provides an overview of 
the different microneedle formulations described in the literature for cancer therapy, 
emphasizing those produced with polymers. The microneedles general properties, type 












2. General Properties of Microneedles 
Microneedle devices are composed of micron-size needles that can be organized in 
single structures or arranged in small arrays to mediate the localized delivery of 
therapeutic molecules [31, 32]. These micro-projections generally present dimensions 
around 50 to 250 μm in wide and lengths that can range from few micrometers to those 
as long as 1500 μm [32, 33]. In general, the microneedles application aims to create a 
transport pathway for the delivery of therapeutic molecules, bypassing the external 
barriers that limit the therapeutics penetration in the target tissue. Further, the 
microneedles devices are compatible with the delivery of both small and 
macromolecular therapeutics such as small drugs (e.g. doxorubicin), proteins (e.g. 
ovalbumin), genetic materials (e.g. pDNA and siRNA), or even nanomedicines [33-35]. 
Additionally, the microneedles are highly versatile and are regarded as less painful, 
damaging, and safer to use, when compared to conventional needles [13]. Moreover, 
the microneedles can be produced using several different materials (e.g. stainless 
steel, titanium, glass, and polymers) and fabrication methods [36-39]. Such results in a 
wide variety of microneedle designs that in general are categorized as solid 
microneedles, drug-coated microneedles, dissolving microneedles, and hollow 
microneedles [13, 31, 40]. As shown in Figure 1, these microneedle designs enable the 
delivery of therapeutics by different mechanisms, which can be explored for the 












Figure 1 – Representation of the main microneedle designs explored for drug delivery 
applications, (A) Solid microneedles, (B) Layered microneedles, (C) Dissolving 
microneedles, and (D) Microneedles drug reservoir.  
Solid microneedles are usually applied for tissue pretreatment in order to increase the 
therapeutic agents’ delivery to the target tissue [41, 42]. In this approach, the 
microneedles insertion and subsequent removal originates micron-scale pores in the 
tissue, allowing the posterior application of a drug formulation, in the form of a drug 
solution or hydrogels, that will diffuse through the pores to deeper regions of the tissue 
[41, 43]. On the other hand, the microneedles can present a layered organization 
where the base layer confers mechanical support for insertion in the target tissue and 
the remaining layers contain the therapeutic molecules [44, 45]. In this way, after the 
microneedles’ application, the dissolution of the different microneedle layers will allow 
the diffusion of the therapeutic molecules to the tissue [46, 47]. Alternatively, the 
microneedles can present the therapeutic agent homogeneously dispersed in the 
microneedles’ polymeric matrix [48]. Therefore, the release of the encapsulated 
payload will occur in a process mediated by the microneedles’ degradation (e.g. 
polymer enzymatic breakdown, hydrolysis, or dissolution) [49-51]. Further, 
microneedles can be engineered to contain a drug deposit and hollow tips with empty 
channels that allow the passage of the drug solution to the target tissue [13, 52]. In this 











controlled and localized delivery of therapeutic molecules directly to the target tissue 
and the ability to easily explore different drug formulations for achieving an enhanced 
therapeutic effect. In the following sections, the application of polymer-based 
microneedles aimed for treating cancer will be described, highlighting the microneedle 
device production method, therapeutic approach, and efficacy. 
3. Microneedles anticancer vaccines 
Cancer vaccination (immune and gene-based therapies) has been receiving a great 
attention by the scientific community in the last years, since it has been revealing 
promising anticancer results [53, 54]. In this field, the utilization of microneedles can be 
advantageous due to its capacity to overcome the skin’s stratum corneum layer and 
deliver its payload upon contact with the interstitial fluid, usually at a depth of superior 
to 200 µm [55, 56]. In fact, when compared to the conventional hypodermic needles, 
the microneedle-based delivery systems avoid the pain and discomfort of the 
hypodermic needle insertion in the skin as well as the creation of hazardous wastes 
[31, 34]. Further, the microneedles contain the vaccine (immune or gene-based) in a 
dried solid form, which increases its thermostability and facilitates the application on 
the target area [35, 57]. 
3.1. Immune therapies 
Cancer immune-based vaccinations purpose to trigger a systemic immune response by 
the host in order to eradicate the tumor tissue (Figure 2) [58]. Such approaches usually 
explore the vaccine delivery to the skin, the largest immunological organ of the body, 
which is densely populated by antigen-presenting cells (APCs), i.e. macrophages, 
Langerhans, and dendritic cells [59]. These APCs, when activated, can stimulate the T 
(CD4+ and CD8+) and B cells and consequently induce a systemic antitumoral immune 












Figure 2 – Representation of the microneedles’ application as anticancer vaccines. The 
loading of peptides, monoclonal antibodies, immune adjuvants, or even genetic 
material on the microneedle devices aims to induce the activation of the immune cells 
triggering an antitumoral response by the host. 
For that purpose, researchers have been exploring the application of microneedle 
patches, containing immunostimulatory adjuvants and/or antigens, as anticancer 
therapeutic approaches. Zaric et al described the application of methylvinylether and 
maleic anhydride microneedles enriched with ovalbumin-loaded poly-D,L-lactide-co-
glycolide (PLGA) nanoparticles for triggering the antigen-specific immune response 
against ovalbumin expressing B16 melanoma tumors [62]. In this approach, the 
authors prepared ovalbumin loaded PLGA nanoparticles via water-in-oil double 
emulsion technique and then added the nanoparticles to a solution of methylvinylether 
and maleic anhydride that was poured on silicone templates to create the microneedles 
(19 by 19 array). These authors observed, in the ex vivo assays, that the microneedles 
could penetrate the murine skin, reaching the dermal layer and the local dendritic cells. 
Further, they also observed that the transfected dendritic cells could migrate to the 











cytokines such as IFN-γ. Moreover, this immune system activation, mediated by the 
nanoparticles release from the microneedles, prevented the development of ovalbumin 
expressing B16 melanoma tumors for 13 days. In a similar way, Kim and colleagues 
developed a microneedle patch composed of Pluronic F127 and polyethylene glycol for 
the simultaneous delivery of resiquimod (R848) and tumor antigens [63]. The R848 is a 
ligand of the human toll-like receptor 7 and 8 (TLR 7/8) expressed by immune cells, like 
macrophages, dendritic and B cells. The R848 interaction with TLR 7/8 can trigger the 
production of IL-12, IFN-γ, and TNF-α and therefore stimulate the antigen-specific 
humoral and Th1 immune responses [64, 65]. Further, this device also mediated the 
simultaneous delivery of ovalbumin to direct the immune response towards E.G7-OVA 
(lymphoma cells expressing ovalbumin) tumor-xenografts. The microneedle array with 
49 pyramid-shaped needles was prepared by depositing a mixture of Pluronic 
F127/R848 and PEG/ovalbumin and drying it at room temperature under vacuum in a 
polydimethylsiloxane (PDMS) mold. Then, it was also noticed that the microneedles 
could penetrate the superficial layers of the mouse skin and allow the diffusion of its 
payload to the adjacent cells. Moreover, the authors as well reported that upon 
dissolution, the microneedles form nanomicelles that could mediate the delivery of 
R848 and ovalbumin to RAW264.7 cells and, consequently, stimulate the production of 
cytokines as well as induce the macrophages maturation. On the other hand, the in 
vivo assays showed that the microneedles loaded with R848 and ovalbumin could not 
only activate the skin APCs but also migrate to lymph nodes. In fact, when comparing 
to the mice treated using hypodermic syringes, the authors reported that the 
microneedles could mediate the generation of higher levels of antigen-specific 
antibodies (37x increase for hypodermic needles and 46 x increase for microneedles) 
and cytotoxic T cells. This improvement in the immune response hindered the E.G7-
OVA tumor growth (tumor weight: ≈2.5g in control group and ≈0.4g on the 
microneedles treated group). Additionally, extended necrotic areas were noticed in the 












Figure 3 – Evaluation of the ovalbumin and R848 loaded microneedles antitumoral 
efficacy on E.G7-OVA tumor bearing mice. (A) Timescale of the cancer cells 
inoculation and therapeutic vaccinations. (B) Analysis of the tumor size progression for 
28 days. (C) Tumor weight measurements at day 28. Reprinted with permission from 
ACS Nano, Vol. 12 (10), Kim, et al., Enhanced Cancer Vaccination by In Situ 
Nanomicelle-Generating Dissolving Microneedles, 9702-9713. Copyright (2018) 
American Chemical Society. 
On the other side, microneedles can be engineered to deliver antibody based immune 
therapies aimed to revert/by-pass the tumor cells’ immune suppressive signals. Ye and 
coworkers produced a hyaluronic acid-based microneedle array for mediating the 
delivery of anti-PD1 antibody (aPD1) and 1-methyl-DL-tryptophan (1-MT) to B16F10 
melanoma tumors [66]. The aPD1 targets the PD-1 receptors expressed by T cells and 
therefore can avoid the cancer cells inhibitory signaling that prevent the T cells 
activation [67]. On the other hand, 1-MT is an inhibitor of the immunosuppressive 











response [68]. The conical shaped microneedle arrays (15 by 15) were produced using 
silicone molds. For that purpose, the authors chemically grafted the 1-MT to the 
hyaluronic acid chains, which subsequently were used to create micelles loaded with 
the aPD1. Then, the micelles were deposited on the silicone molds, dried, coated with 
additional 1-MT modified hyaluronic acid, and dried at room temperature under vacuum 
to obtain the microneedles. The authors observed that the 1-MT and aPD1 release 
occurred in response to the HAase-triggered degradation of the microneedles and 
micelles [66]. Further, the microneedles presented a fracture force of 0.41 N, which 
allowed them to penetrate the mice’s dorsum skin and, consequently, deliver its 
payload at a depth of 200 µm. Additionally, the microneedles administration on mice 
bearing B16F10 melanoma cells increased the retention of 1-MT and aPD1 at the 
tumor tissue. In fact, the accumulation of 1-MT on melanoma was 3-fold higher at day 1 
and 5-fold higher at day 2 and 3 on the group treated with the microneedles than in that 
treated with free 1-MT. Moreover, the simultaneous delivery of aPD1 and 1-MT by the 
microneedles impaired the tumor progression (tumor area inferior to 50 mm2, whereas 
in the control group the area was superior to 300 mm2) and increased the mice survival 
rate. On the other hand, Wang and colleagues explored the development of hyaluronic 
acid microneedles for the delivery of aPD1 and glucose oxidase loaded dextran 
nanoparticles for the treatment of skin cancer [69]. In this approach, the aPD1 and 
glucose oxidase loaded dextran nanoparticles were deposited on silicone molds that 
were subsequently filled with acrylate modified hyaluronic acid and N,N’-
methylenebisacrylamine allowing the microneedles formation (15 by 15 array) upon 
exposition to UV light. The glucose oxidase can mediate the generation of gluconic 
acid from the glucose present in the medium and consequently promote the 
nanoparticles dissociation and the aPD1 release [70]. The authors showed that the 
produced microneedles presented a failure force of 0.38N/needle, which allowed its 
penetration into the mouse skin up to 200 µm in depth. Additionally, in vivo assays 











of aPD1 could efficiently stimulate the CD 8+ T cells infiltration into the tumor tissue (% 
of CD 8+ T cells increased from 30% to 43% when comparing the groups treated with 
free aPD1 and microneedles). Such improvement resulted in a significant tumor 
inhibition/regression as well as an increase in the mice survival rate, 40% of mice 
survived for 40 days after microneedles treatment, whereas the mice treated with free 
aPD1 only survived for 30 days.  
3.2. Gene therapies 
Apart from the application of microneedles for mediating the immune system activation 
through the delivery of antigens, adjuvants, or even antibodies, these macroscale 
delivery devices have been also explored for the administration of antitumoral gene 
therapies. Ali and colleagues developed a polyvinylpyrrolidone microneedle patch 
loaded with E6/E7 pDNA RALA nanoparticles for the treatment of cervical cancer [71]. 
The microneedles were produced using a micromolding process, by depositing a PVP 
solution containing E6/E7 pDNA/RALA nanoparticles on a negative mold. Additionally, 
the authors observed that upon manual application 90% of needle length could be 
inserted on the porcine skin and that after 15 min the microneedles tips were already 
completely dissolved within the skin layers. Further, the authors demonstrated that 
after microneedles administration the concentration of antibodies was 2 times higher 
than that of the control and the T cells were more responsive to HPV-16 oncogenic 
antigen expressing cells (TC-1) (IFN-γ levels in control ≈250 pg/mL and ≈530 pg/mL for 
microneedle immunized group). This enhanced immune response prevented the 
establishment of cervical tumors on 4 of the 9 mice treated with microneedles. 
Moreover, the authors also reported that the microneedles administration on mice 
bearing cervical tumors induced the regression of the tumor area, 246 mm2 
microneedle treated mice and 503.13 mm2 for mice vaccinated with RALA-E6/E7 
nanoparticles. Alternatively, Pan and coworkers utilized dextran/hyaluronic 











polyethyleneimine/STAT3 siRNA complexes to skin melanoma tumors (Figure 4) [72]. 
STAT3 is a protein overexpressed in several tumors (e.g. melanoma, breast, and 
prostate) that can prompt the cancer cells proliferation, angiogenesis, survival, and 
immune evasion [73]. These microneedles were produced by blending 
polyethyleneimine/STAT3 siRNA complexes with a dextran/hyaluronic 
acid/polyvinylpyrrolidone solution, followed by the casting in PDMS molds of pyramidal-
shaped needles (12 by 12 arrays). 
 
Figure 4 – Morphological characterization of the microneedle devices loaded with 
polyethyleneimine/STAT3 siRNA complexes. (A) Macroscopic photographs of the 
microneedles. (B) Scanning electron microscope images of the microneedle patches. 
(C) Analysis of the complexes loading on the microneedles through confocal laser 
scanning microscope. 
The authors reported that almost 100% of microneedles tips penetrate the rat skin 
when forces superior to 20N are applied, microneedles have failure force 86N, which 
allows the delivery of the polyethyleneimine/STAT3 siRNA complexes at a depth of 
330µm [73]. Further, the authors also observed that the topical administration of STAT3 
siRNA mediated by the microneedles could reduce the STAT3 mRNA expression in 
30% as well as induce the necrosis of 40% of the tumor cells. Such effect inhibited the 
growth of the melanoma tumor, registering a tumor weight 5 times lower than the 
control.  
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4. Local administration of anticancer therapeutic agents 
In recent years, the microneedles arisen as an alternative to the chemotherapeutics 
systemic administration (Figure 5). This local administration of the therapeutic agents 











effects [4]. Further, when comparing to the intra-tumoral administration of liquid drug 
formulations, the microneedles provide a better spatial and temporal control over the 
therapeutics release to the tumor tissue, which can limit the drug leakage to the 
adjacent healthy tissues [76].  
 
Figure 5 – Representation of the microneedles’ application as delivery devices for 
cancer therapy. The microneedles can transport and mediate the delivery of 
conventional anticancer drugs, photothermal and photodynamic agents as well as 
nanomedicines.  
Zhao and colleagues developed an hyaluronic acid based microneedle patch loaded 
with 5-aminolevulinic acid for the photodynamic therapy of subcutaneous tumors [77]. 
The 5-Aminolevulinic acid can be converted into protoporphyrin IX (PPIX) in cell 
mitochondria, acting as a photosensitizer by mediating the production of highly reactive 
oxygen species upon light irradiation. The microneedles were produced by depositing a 
hyaluronic acid solution containing 5-aminolevulinic acid on PDMS molds of pyramidal-
shaped tips (5 by 5 arrays). The authors observed that the microneedles could 











600 µm in 2 min. Further, the authors also demonstrated that the photodynamic 
therapeutic effect mediated by the microneedles could induce a decrease on the tumor 
volume. In fact, mice treated with microneedles and subjected to the light irradiation 
(635 nm, 450 mW, for 10 min) presented a reduction of the initial volume of the tumor to 
44% in just 7 days, whereas the group treated with free 5-aminolevulinic acid and light 
the tumor volume increased in 455% (Figure 6). Such data demonstrated that the 
microneedles-mediated local administration can improve the drug bioavailability, 
avoiding the non-specific interactions and degradation during blood circulation.  
 
Figure 6 – Evaluation of the 5-aminolevulinic acid (ALA) loaded hyaluronic acid-based 
microneedle patches antitumoral efficacy. (A) Analysis of the tumor growth and (B) 
photographs of the tumor bearing mice. (C) Analysis of the tumor weight after 14 days 
and (D) photographs of the excised tumors. Reprinted from Journal of Controlled 











for photodynamic therapy of subcutaneous tumor, 201-209. Copyright (2018), with 
permission from Elsevier. 
On the other hand, microneedles can also mediate the simultaneous delivery of 
different therapeutic agents such as drug-drug and drug-nanoparticle combinations for 
improving the efficacy of anticancer treatments. Bhatnagar and coworkers developed a 
polyvinylpyrrolidone/polyvinyl alcohol microneedle patch for the combinatorial delivery 
of doxorubicin and docetaxel to breast cancer tumors [29]. Doxorubicin and docetaxel 
are two chemotherapeutics commonly used to treat this type of cancer. Doxorubicin is 
a non-selective class I anthracycline that can induce the cell death by intercalating with 
the DNA and suppressing the macromolecules biosynthesis [78]. On the other hand, 
docetaxel interferes with the normal function of microtubule growth affecting the 
cytoskeleton flexibility and cell mitosis [79]. In this approach, the drugs were 
incorporated on the microneedles tips by dissolving them on the polyvinylpyrrolidone 
solution [79]. Then, this solution was deposited on a PDMS mold of pyramidal-shaped 
needles and coated with a polyvinylpyrrolidone/polyvinyl alcohol mixture to further 
increase the patch mechanical strength. The authors observed that this methodology 
allowed the production of microneedles with a compression strength superior to 5N, 
which endured the insertion on the mice skin being detected the drug delivery until a 
depth of 140µm. Further, the authors described that the microneedles patch was 
completely dissolved in 33 min, with 90% of the docetaxel being released in the first 15 
min. Additionally, the in vivo studies performed on 4T1 breast tumors bearing mice 
revealed that the combinatorial delivery of doxorubicin and docetaxel was more 
efficient than the single treatment approaches leading to an impaired tumor growth. 
Moreover, when compared to the free drug administration, the increased mice survival 
rate and the long-term maintenance of the mice weight demonstrated that the 
microneedles-mediated chemotherapeutic administration also mitigate the drugs non-











microneedles for mediating the delivery of doxorubicin and indocyanine green to the 
synergistic chemo- and photothermal-therapy of osteosarcoma tumors [80]. 
Indocyanine green is a dye that can induce cancer cells death through the production 
of heat and/or singlet oxygen upon irradiation with near-infrared (NIR) light [81]. For 
this purpose, the authors encapsulated the indocyanine green on mesoporous silica 
nanoparticles and blended them with a solution, composed of doxorubicin and 
polyvinylpyrrolidone, that was casted on PDMS molds of pyramidal needles (10 by 10 
arrays) [81]. The microneedle patches presented a compressive strength of 0.37N and 
achieved a complete penetration of skin stratum corneum when a force of 0.03N was 
applied. Moreover, the authors observed in vitro that upon NIR light irradiation (808 nm, 
0.34 W.cm-2, 1 min), the microneedles could mediate an increase in the temperature to 
values superior to 50ºC. In fact, the microneedles application on subcutaneous tumors 
and subsequent NIR light irradiation (808 nm, 0.34 W.cm-2, 2 min) induced an increase 
in the temperature of the tumor tissue up to 48ºC. Additionally, the authors also 
reported that the combination of the photothermal effect with the doxorubicin action 
provoked a decrease in the tumor volume to 50% and induced the necrosis of ≈80% of 
the tumor cells. Hao and colleagues also explored the combinatorial application of 
nanoparticles and drugs, i.e. gold nanorods and doxorubicin, for the chemo- and 
photothermal-therapy of human epidermoid cancer therapy [82]. The gold nanorods are 
one type of NIR responsive nanomaterials, due to the surface plasmon resonance 
phenomenon, that can be used for mediating a photothermal effect [83]. In this 
strategy, the gold nanorods, doxorubicin, and hyaluronic acid were blended and casted 
on a PDMS template of 20 by 20 microneedle patches [82]. The authors demonstrated 
that upon NIR light irradiation (808 nm, 1 W.cm-2, 5 min), these patches could induce 
an increase in the temperature up to 65ºC. Additionally, this temperature increase 
could also expedite the doxorubicin release to the adjacent tissue. In the in vitro 
assays, the authors observed that the microneedles (loaded with the drug) were able to 











Nevertheless, in the in vivo assays, the authors demonstrated that the microneedles 
local administration and controlled release of both gold nanorods and doxorubicin 
renders a superior antitumoral efficacy. In fact, the combinatorial treatment mediated 
by the microneedles resulted in the complete remission of the A431 tumors, contrasting 
with the slightly inhibited tumor growth on the stand-alone therapies (i.e. free drug, 
microneedles mediated chemotherapy, or microneedles mediated photothermal effect). 
Similarly, Dong and coworkers developed a gold-nanocage and doxorubicin loaded 
hyaluronic acid microneedles for the transdermal photothermal and chemo-therapy of 
skin tumors [84]. For this purpose, PDMS molds were filled with a solution containing 
doxorubicin and gold nanocages. Then, the samples were dried, and a solution of 
hyaluronic acid was added to the previous PDMS molds, originating microneedles 
patches (10 by 10 arrays) with pyramidal needles enriched with doxorubicin and gold 
nanocages. The authors observed that the inclusion of the gold nanocages improved 
the microneedles mechanical strength, the young modulus increased from 68.9 to 
224.9 MPa, which is crucial for facilitating the microneedles penetration of the skin’s 
stratum corneum and accomplish a 220 µm penetration depth. Further, these authors 
also demonstrated that the local administration of the microneedles on subcutaneous 
melanoma tumors could induce a temperature increase up to 55ºC when irradiated with 
a NIR light (808nm, 1 W.cm-2, 1 min). This localized delivery of doxorubicin and gold 
nanocages to melanoma tumors peaked at 24h and the authors observed that the 
therapeutics still remained in the tumor tissue after 72h. Moreover, despite the authors 
did not report any significant difference on the antitumoral effect mediated by the 
microneedles and the intra-tumoral administration of free doxorubicin and gold 
nanocages (both treated tumors presented a size 83% smaller that the non-treated 
group), the microneedles successfully reduced the therapeutics non-specific toxicity, 
being observed a reduction on the mice weight in the free therapeutics treated group 












Figure 7 – Evaluation of the in vivo antitumoral capacity of gold nanocages and 
doxorubicin loaded hyaluronic acid microneedles. (A) Analysis of the tumor volume 
progression during the 12 days. (B) Tumor weight measurements at day 12. (C) Body 
weight analysis and (D) Survival rates of the C57 mice. Reprinted with permission from 
ACS Applied Materials and Interfaces, Vol. 10 (11), Dong, et al., Au Nanocage-
Strengthened Dissolving Microneedles for Chemo-Photothermal Combined Therapy of 
Superficial Skin Tumors, 9247-9256. Copyright (2018) American Chemical Society. 
Alternatively, some authors also have been exploring the application of microneedle 
devices for the high-throughput screening of the tumors’ drug sensitivity. These 
approaches aim to simultaneously test a range of therapeutics on a in vivo tumor as 
well as evaluate the patient individual responsiveness to a specific therapeutic agent or 
therapeutic combinations. For this purpose, Jonas and colleagues developed a 
microscale needle containing several drug reservoirs, each with a unique single agent 











evaluation of the tumor drug sensitivity (Figure 7) [30]. This cylindrical device with 820 
µm of diameter and 4 mm in length, presented up to 16 drug reservoirs in its surface 
and could be implanted into the tumors through a biopsy needle. Then, the drugs can 
diffuse into different tumor regions of 200-300 µm, the drug diffusion can be controlled 
(i.e. delay or favor) by modulating the reservoir size, incorporation of polymer matrixes, 
and utilization of expansive hydrogels.  
 
Figure 8 – (A) Representation of the microneedle device application as a drug 
screening device. The device can be implanted directly on the tumor tissue, allowing 
the drugs diffusion from the reservoirs to confined regions in the tumor. This behavior 
allows to evaluate the tumor-specific response to a determined drug. (B) Effect of the 











can be controlled by the reservoir size, drug-polymer matrix formulation, or by the 
utilization of expansive hydrogels. From Science Translational Medicine, Vol. 7, Jonas, 
et al., An implantable microdevice to perform high-throughput in vivo drug sensitivity 
testing in tumors, 284ra57. Reprinted with permission from AAAS. 
The authors observed that this device could restrict the drug release from each 
reservoir to individual tumor regions and the therapeutics combination could be 
achieved by encapsulating the different compounds into the same reservoir. Further, 
the authors also reported that this control over the therapeutics release could match 
the intra-tumoral drug concentration achieved by the systemic administration of the 
therapeutics, i.e. tumor zones with drug levels of 8 to 13 mg/kg or 3 to 7 mg/kg, which 
strengthens the translation of the results obtained with this device to the clinic. 
Moreover, the authors evaluated the device capacity to act as a predictor of the 
systemic efficacy in three human cancer mouse models (A375 melanoma, BT474 
breast, and PC-3 prostate) demonstrating that the doxorubicin could induce the highest 
apoptotic index (55%) on A375 cells followed by BT474 and PC-3 cells (18% and 8%, 
respectively). These data were coherent with those obtained from the mice treated 
through intravenous administration, apoptotic index of 34.9% and 8.7% for A375 and 
PC-3 cells respectively. In this way, the authors also demonstrated that this 
microneedle device can be used to determine the most effective drug formulation 
towards a specific tumor. For example, the authors reported that for the microneedle 
device treated groups the paclitaxel presented the highest apoptotic index (54%) 
against triple-negative breast cancer tumors, followed by doxorubicin (36%), cisplatin 
(25%), gemcitabine (12%), and lapatinib (4%). Moreover, the microneedle device also 
allowed the authors to determine the best drug combinations, for example on BT474 
tumors, the combination of doxorubicin with sunitinib leads to an increase of the 
apoptotic response from ≈3% to ≈5.5%, this apoptotic response was further improved 











Davidson and colleagues also utilized the previous microneedle device to demonstrate 
that pancreatic cancer cells can use extracellular proteins (e.g. albumin) as a source of 
amino acids, which can translate to a preferential uptake of albumin based 
nanocarriers and improve the tumor delivery of therapeutics [85].  
Table 2 – Overview of the microneedles’ application as drug delivery devices for cancer 
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5. Conclusions and future perspectives 
Despite all the efforts, the systemic anticancer therapeutic approaches still present 
several disadvantages such as the excessive complexity to be adequately applied in 
the clinic and undesired interactions with healthy tissues. Therefore, the development 
of macroscale delivery systems that can be locally implanted on the tumor tissue and 
by-pass all the hurdles of the systemic delivery have been showing promising results 
for cancer therapy. As an emerging delivery device, the microneedles can be used to 
efficiently deliver both small and macromolecules, such as chemotherapeutics, 
proteins, and genetic material, or even nanoparticle-based anticancer therapies. 
Moreover, the microneedles can be fabricated using diverse materials and different 
methods allowing a great diversity on the device design and therapeutics release. As 
highlighted in this review, microneedle-based devices have the potential to deliver 
simultaneously combinations of drugs and photodynamic agents, nanoparticles and 
drugs, genetic material and antibodies, and others. Nevertheless, despite the great 
potential of microneedles for improving the efficacy of the commonly applied anticancer 
therapies, several comprehensive studies are still necessary to fully characterize the 
behavior of these microscale drug delivery devices on human therapeutic applications. 











important parameters, such as the timing for combining the action of these different 
strategies, the therapeutics concentration, the exposure time, and the release 
sequence. In this field, the combination of microneedles with layer-by-layer production 
techniques can be a highly promising and straightforward approach to allow the 
production of complex and hierarchically organized structures. Further, these 
microneedle devices carry the potential for improving not only the efficacy of anticancer 
therapies but also improve the transdermal drug delivery in the context of other health 
disorders. 
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